Adaptimmune Therapeutics plc

OTCPK:ADAP.Y Stock Report

Market Cap: US$8.0m

Adaptimmune Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:ADAP.Y Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Aug 25SellUS$348William Charles BertrandIndividual34,500US$0.01
18 Aug 25SellUS$38,195New Enterprise Associates, Inc.Company3,250,000US$0.012
30 Jul 25SellUS$1,148,373EcoR1 Capital, LLCCompany10,675,423US$0.11

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ADAP.Y?
Owner TypeNumber of SharesOwnership Percentage
Institutions3,9350.00148%
Individual Insiders1,713,4780.646%
General Public263,387,18899.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 12 shareholders own 0.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.26%
Garry Menzel
686,295US$20.6k0%no data
0.15%
Adrian George Rawcliffe
395,227US$11.9k0%no data
0.064%
John Lunger
170,890US$5.1k0%no data
0.062%
William Charles Bertrand
164,392US$4.9k0%no data
0.05%
Elliot Norry
133,265US$4.0k0%no data
0.042%
Cintia Piccina
111,073US$3.3k0%no data
0.009%
Lawrence Alleva
23,894US$716.40%no data
0.006%
Gavin Hilary Wood
16,000US$480.30%no data
0.0047%
Joanna Brewer
12,442US$372.90%no data
0.0014%
Rhumbline Advisers Ltd Partnership
3,661US$109.70%no data
0.0001%
Guggenheim Partners, LLC
273US$8.00%no data
0%
New Enterprise Associates, Inc.
1US$00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 07:54
End of Day Share Price 2026/06/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adaptimmune Therapeutics plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBofA Global Research
Mohit BansalCitigroup Inc
Reni BenjaminRaymond James & Associates